Intellia Therapeutics' NTLA-2002 CRISPR treatment reduces HAE attacks by 98% after one dose in an ongoing Phase 1 study.
Intellia Therapeutics reports long-term data from Phase 1 of its ongoing study for NTLA-2002, an experimental in vivo CRISPR gene-editing treatment for hereditary angioedema (HAE). Results from the 20-month follow-up show a 98% mean reduction in monthly HAE attack rates after a single dose. Eight of 10 patients remain attack-free, and NTLA-2002 demonstrates a favorable safety and tolerability profile.
June 02, 2024
4 Articles